Evolus filed three material events (March 13, May 4, June 12, 2026) indicating significant changes to Jeuveau pricing, rebate structure, or the Evolus Rewards loyalty program. Evolus has historically positioned Jeuveau as a lower-cost alternative to Allergan Botox, with aggressive rebate programs targeting independent medspas and mid-market practices. These filings suggest active repositioning, likely in response to market share pressure or margin compression in the toxin category.